These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarZacks Investment Research • 4h
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 EarningsZacks Investment Research • Thursday
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research • Thursday
Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It MattersThe Motley Fool • Tuesday
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockMarketBeat • Monday
Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • Monday
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 StudyBusiness Wire • Monday
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?The Motley Fool • 10/25/26
Buy 8 Barron's Big Better Bets (Than T-Bills) Out Of 14 'Safer' October DiviDogsSeeking Alpha • 10/25/26
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 10/23/26